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ABSTRACT
Nucleophosmin (NPM) is known to regulate ARF subcellular localization and 
MDM2 activity in response to oncogenic stress, though the precise mechanism has 
remained elusive. Here we describe how NPM and ARF associate in the nucleoplasm 
to form a MDM2 inhibitory complex. We find that oligomerization of NPM drives 
nucleolar accumulation of ARF. Moreover, the formation of NPM and ARF oligomers 
antagonizes MDM2 association with the inhibitory complex, leading to activation of 
MDM2 E3-ligase activity and targeting of p53. We find that AKT phosphorylation 
of NPM-Ser48 prevents oligomerization that results in nucleoplasmic localization of 
ARF, constitutive MDM2 inhibition and stabilization of p53. We also show that ARF 
promotes p53 mutant stability in tumors and suppresses p73 mediated p21 expression 
and senescence. We demonstrate that AKT and PI3K inhibitors may be effective in 
treatment of therapeutically resistant tumors with elevated AKT and carrying gain of 
function mutations in p53. Our results show that the clinical candidate AKT inhibitor 
MK-2206 promotes ARF nucleolar localization, reduced p53mut stability and increased 
sensitivity to ionizing radiation in a xenograft model of pancreatic cancer. Analysis 
of human tumors indicates that phospho-S48-NPM may be a useful biomarker for 
monitoring AKT activity and in vivo efficacy of AKT inhibitor treatment. Critically, we 
propose that combination therapy involving PI3K-AKT inhibitors would benefit from 
a patient stratification rationale based on ARF and p53mut status. 
INTRODUCTION
The phosphatidylinositol 3 kinase (PI3K)-AKT 
signaling cascade is a vital mediator of essential cellular 
activities including proliferation and survival [1]. 
Mutations, amplification and deletions of the upstream 
regulators of AKT are among the most frequent somatic 
events in cancer [2, 3]. Consequently, deregulation of 
AKT is a major factor enhancing both oncogenesis and 
resistance to treatment in many human malignancies [4, 
5]. Alteration of upstream pathway components, such as 
activating mutations in RAS, PI3K or loss of PTEN, can 
be the primary oncogenic event leading to therapeutic 
failure[2, 6] . However, it is the activation of AKT that is 
proposed to modulate cell death responses to therapeutic 
agents and mediate resistance [3, 7]. Not surprisingly, 
the aim of regaining sensitivity to various therapies has 
focused attention on targeting the PI3K-AKT pathway 
[8]. PI3K and AKT inhibitors, such as PI-103 and MK-
2206 have been investigated as single agents, but their 
potential as combination agents in specific patient cohorts 
is anticipated to be where the greatest effectiveness of 
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these agents will be identified [9, 10]. 
TP53 is an important mediator of cell death 
responses to commonly used therapeutic agents that 
elicit DNA damage [11-13]. The potent tumor suppressor 
functions of p53 require that the activity of this protein 
is under tight control to prevent unnecessary induction of 
apoptosis or cellular senescence [14-16]. In untransformed 
cells p53 is targeted for proteasomal degradation by the 
E3 ubiquitin ligase MDM2 [17]. The activity of MDM2 is 
antagonized by p14ARF (p19ARF in mouse – hereafter ARF), 
a product of the INK4A/ARF locus [18]. In untransformed 
cells, ARF mediated inhibition of MDM2 and subsequent 
p53 activation is important in the induction of p53 tumor 
suppressor activities, including the activation of cellular 
senescence following oncogenic insult [19-22]. 
The functional inactivation of the p53 pathway, 
either through mutation of p53 itself or the deregulation 
of upstream regulatory elements is a universal feature of 
human cancer [16, 23]. Indeed somatic mutations of p53 
are found in nearly half of all human cancers [24, 25]. 
Recently, mutant p53 (p53mut) has been demonstrated to 
respond to many of the same stimuli that promote wild 
type p53 stabilization, indicating that wild type and mutant 
p53 share similar regulatory mechanisms [26]. 
A hallmark of tumors with missense mutations in 
p53 is the accumulation of p53mut within tumor tissue, 
which contributes to the many gain of function phenotypes 
attributed to p53mut [24, 25]. Furthermore, many genetic 
modifications found in cancer including RAS mutation, 
c-MYC activation, p16INK4A loss or PML deletion have 
been demonstrated to stabilize p53mut [26-28]. In normal 
tissue, mutation of p53 alone is in itself not sufficient to 
promote p53mut accumulation. Furthermore, as tumors 
originating from p53mut mice do not accumulate p53mut 
to the same degree, it suggests that there may be some 
degree of tissue specificity regarding the mechanisms 
which contribute to p53mut stability [27, 29, 30]. Growing 
evidence indicates that tumor cells must also acquire 
additional mutations for p53mut to overcome regulatory 
mechanisms that normally protect against inappropriate 
p53 accumulation in normal cells [24, 25, 27, 31, 32]. 
Although MDM2 has been demonstrated to restrict the 
stabilization of p53mut [27] the molecular determinants 
and pathways that promote p53mut stabilization remain to 
be fully determined and have the potential to offer new 
therapeutic avenues to the treatment of tumors harboring 
p53mut. 
In human tumors ARF is infrequently mutated and 
predominately inactivated through promoter methylation 
or transcriptional inactivation. While ARF activity maybe 
lost due to mutations at the INK4A/ARF locus, a number 
of studies have shown that they can be mutually exclusive, 
where INK4A maybe lost while sparing ARF [33]. 
Although ARF expression has been reported in cell lines 
with p53mut and has been suggested to protect p53mut from 
degradation [34, 35], it is unclear whether ARF contributes 
to the regulation of p53mut. 
ARF itself is regulated by nucleophosmin (NPM), a 
predominantly nucleolar protein, which due to the presence 
of multiple sub-cellular localization signals shuttles 
between the nucleolus, nucleoplasm and cytoplasm [36, 
37]. NPM is required for both ARF stability and targeting 
to the nucleolus [38-41]. Indeed NPM has been proposed 
to sequester ARF in the nucleolus, preventing it from 
inhibiting MDM2 [41, 42]. The importance of NPM in 
regulating ARF stability is highlighted by the frequent 
somatic mutation in acute myeloid leukemia (NPMc) 
which increases the trafficking of NPM to the cytoplasm 
resulting in increased ARF turnover [43, 44]. Given 
that ARF has been proposed to inhibit MDM2 in the 
nucleoplasm and nucleolar localization of ARF protects 
it from degradation, a conundrum exists regarding the 
mechanism that allows NPM to restrict ARF nucleolar 
accumulation and thereby allow MDM2 inhibition [41, 
45-48] 
In this article we identify that AKT regulates both 
ARF stability and localization at the nucleolus. We find 
that AKT phosphorylation of NPM-Ser48 inhibits NPM 
oligomerisation and localization at the nucleolus. This 
in turn promotes ARF mediated inhibition of MDM2 in 
the nucleoplasm. Importantly, AKT mediated promotion 
of ARF localization in the nucleoplasm facilitates 
oncogenesis by promoting p53mut stability and dominant 
negative suppression of the DNA damage response, 
thereby contributing to therapeutic resistance. We provide 
molecular evidence for resensitization of tumors by PI3K-
AKT inhibitors. Most importantly, our findings indicate 
that AKT mediated resistance associates with INK4A/
ARF status and p53mut, therefore identifying a screening 
rationale for the patient population in which PI3K-AKT 
inhibitors are most likely to display efficacy. 
RESULTS
AKT phosphorylation of NPM-Ser48 regulates 
NPM oligomerization
NPM was identified by mass spectrometry in AKT 
immunoprecipitates and verified to associate with active 
AKT by western blot (Fig. 1A, S1A and S1B). Although 
other groups have reported an interaction between AKT 
and NPM [49], a role for this association has not been 
addressed. In T24 cells with oncogenically active AKT, 
NPM is readily detectable using a pan-AKT substrate 
antibody but not in the presence of the PI3-kinase inhibitor 
PI-103, indicating that NPM was a possible AKT substrate 
(Fig. S1C). NPM contains a single non-consensus 
(RxxS) AKT substrate motif at position Ser48 within the 
N-terminal oligomerisation domain (Fig. 1B) and the RxxS 
motif has previously been reported to function as a bona-
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fide AKT substrate recognition motif in CDK2 [50]. We 
confirmed that AKT specifically phosphorylated NPM on 
Ser48 by in-vitro kinase assay (Fig. 1C). Phosphorylated 
NPM, but not a NPM-S48A derivative, can be detected 
with a specific phospho-peptide antibody (pS48-NPM) 
(Fig. 1D and S1D) and furthermore, NPM-Ser48 could be 
phosphorylated by AKT in response to EGF stimulation 
(Fig. S1E). 
In order to determine how AKT mediated 
phosphorylation regulates NPM function, we examined the 
crystal structure of the NPM N-terminal oligomerisation 
domain [51]. The structure of the monomer indicates that 
phospho-Ser48 can be accommodated (Fig. S1F) but is 
incompatible with incorporation into the pentameric ring 
due to steric clashes at the monomer-monomer interface 
(Fig. 1E). To address if phosphorylation of NPM-S48 
regulated NPM oligomerisation, Npm-/-; p53-/- MEF 
(hereafter Npm-/- MEF) were reconstituted with NPM-WT, 
non-phosphorylatable NPM-S48A or phosphomimetic 
NPM-S48E derivatives (Fig. 1F and S1G) and lysates 
from reconstituted Npm-/- MEF were resolved under native 
conditions. In agreement with previous studies [52], NPM 
was detected as both a monomer and an oligomer by 
appropriate semi-native electrophoresis conditions (Fig. 
1F, lane 4, Fig. S1G and S1H). The non-phosphorylatable 
NPM-S48A appeared more oligomeric and the 
phosphomimetic mutant, NPM-S48E, although less stable 
under stronger denaturing conditions, was exclusively 
Fig.1: AKT Phosphorylates NPM on Serine 48 and Regulates NPM Quaternary Structure. (A) AKT or IgG 
immunoprecipitates and whole cell lysates from T24 cells were probed with indicated antibodies. (B) (Top) Domain structure of NPM 
highlighting the nuclear export signals (NES) (yellow), nuclear localization signals (green) and nucleolar localization signal (red); (Bottom) 
Sequence alignment illustrating the conservation of Ser48 within the first NES. (C) In-vitro kinase assay of immunopurified AKT or IgG 
control with NPM mutants in the presence of radiolabeled (γ32P) ATP as indicated. (D) Anti-FLAG immunoprecipitates from T24 cells 
transfected with empty vector (con), FLAG-NPM-WT or FLAG-NPM-S48A. Immunoprecipitates and whole cell lysates were probed with 
the indicated antibodies. (E) Ribbon diagram of the NPM pentameric ring (top view) showing a space filling model of phosphorylation at 
Ser48, highlighting a steric clash with the neighbouring subunit. Model is based on PDB entry 2P1B. (F) Npm-/-, p53-/- double null MEF 
were infected with pBabe retrovirus expressing FLAG-tagged-myristoylated (myr)-AKT1 or HA-tagged-myr-AKT2 in combination with 
NPM-WT or NPM-S48A as indicated. NPM oligomerisation status was determined by mild semi native gel electrophoresis (Fig. S1H) and 
denatured lysates, which were probed with the indicated antibodies.
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monomeric (Fig. S1G), as has previously been reported for 
NPM mutants that cannot oligomerize [52]. Interestingly, 
we observed that NPM-S48A oligomers were more 
resistant to mild denaturing conditions (Fig. S1H). Recent 
mathematical modeling predicted that Ser48 should be 
important for controlling the NPM monomer:oligomer 
equilibrium [53]. As NPM oligomerization is incompatible 
with phospho-S48-NPM, we wished to confirm whether 
AKT could inhibit oligomerisation as suggested by the 
NPM-S48E phospho-mimetic mutant (Fig. S1G). 
To determine the effect of AKT activation on 
NPM oligomerization we examined the reconstituted 
Npm-/- MEFs in the presence or absence of constitutively 
active AKT1 or AKT2 (Fig. 1F). In the presence of 
myr-AKT1, we observed an increased monomeric 
NPM fraction, corresponding with increased NPM-S48 
phosphorylation, implying that phosphorylation prevents 
NPM oligomers in a Ser48 dependent manner (Fig. 1F, 
lanes 4-6). Co-expression of K-RasV12, thereby enhancing 
PI3K-AKT activity, similarly disrupts pentameric NPM 
but not NPM-S48A (data not shown). Thus, oncogenic 
activation of AKT disrupts NPM quaternary dynamics via 
phosphorylation of Ser48. 
Phosphorylation of NPM-Ser48 controls NPM 
and ARF localization
NPM isolated from the nucleolus is predominantly 
oligomeric in nature [54] and as phosphorylation of 
Ser48 influences NPM oligomerisation we next wished to 
address if NPM-Ser48 was regulating NPM localization. 
Ser-48 lies within a characterized nuclear export sequence 
(NES) (Fig. 1B) [55], and interestingly mutation of 
either NPM NES has been shown to impair the nucleolar 
localization of NPM [56]. In order to address this, Npm-
/- MEF were reconstituted with NPM-WT or NPM-S48A 
and levels of phospho-S48-NPM were determined by 
immunofluorescence (Fig. 2A). Phosphorylation was 
only detected in cells expressing wild type NPM and 
constitutively active myr-AKT1, but not in NPM-S48A 
expressing cells (Fig. 1F and 2A). In contrast to total 
NPM staining in cells expressing NPM or NPM-S48A, 
phospho-S48 NPM was not localized to the nucleoli 
and was instead distributed throughout the nucleoplasm 
and cytoplasm (Fig. 2A), agreeing with previous reports 
that non-oligomeric NPM is deficient in nucleolar 
targeting [52, 56]. This suggests that phosphorylation of 
NPM-Ser48 is a physiological signal that directs NPM 
localization via the regulation of NPM oligomerisation. 
Since phosphorylation of NPM-Ser48 appears to 
dictate both NPM oligomerisation and localization, we 
wished to address whether this mechanism may also affect 
NPM interacting proteins that are functionally controlled 
by trafficking to and from the nucleolus [36]. Importantly, 
NPM has been widely observed to regulate both ARF 
protein stability and localization [38, 40-42, 52]. Moreover, 
site directed mutants of NPM that restrict oligomerization 
also perturb ARF association and nucleolar targeting 
[39, 52, 56], suggesting that phosphorylation of NPM-
Ser48 by AKT may also impact ARF localization and 
stability. To test this, we transfected Npm-/- MEFs with 
both Flag-NPM and Flag-NPM-S48A and determined 
the ability of these derivatives to co-immunoprecipitate 
ARF (Fig. 2B). We found that while both derivatives are 
capable of binding ARF, cells expressing NPM-S48A have 
elevated total ARF protein levels, indicative of enhanced 
ARF stabilization (Fig. 2B). Thus, Ser48-NPM does not 
directly influence the ability of NPM to associate with 
ARF but results in differential ARF stability. Increased 
ARF stability is associated with nucleolar protection from 
ubiquitin ligase mediated degradation [57], suggesting that 
nucleolar localization of ARF may be affected. We next 
examined ARF localization in Npm-/- MEFs and found 
that endogenous ARF displays a diffuse nucleoplasmic 
staining, but reconstitution with NPM-WT restricts ARF 
localization to distinct punctuate nucleolar foci [38] and 
increases ARF immunofluorescence intensity (Fig. 2C 
and 2D). Expression of NPM-S48A results in an elevation 
of ARF staining (Fig. 2C), which suggests, together with 
Fig. 2B, that higher protein levels are associated with 
localization to the nucleolus (Fig. 2D). To determine 
whether constitutive phosphorylation on Ser48 would have 
the opposite effect on ARF stability and localization, we 
expressed the phosphomimetic derivative, NPM-S48E that 
displays similar localization to phospho-S48-NPM (Fig. 
2A and 2C) and also fails to associate into pentamers (Fig. 
S1G). This derivative is less stable than NPM-WT making 
direct comparisons on overall ARF stability in lysates 
difficult. However, we clearly see that cells expressing 
NPM-S48E are unable to promote any nucleolar NPM 
or ARF (Fig. 2D). Expression of myr-AKT in these cells 
results in increased monomers and disruption of NPM 
nucleolar signal of the NPM-WT, although oligomers and 
foci are still visible (Fig. 1F & 2A). NPM is known to 
form stable oligomers and localize with the fibrillar center 
of the nucleolus but also is found in the nucleoplasm and 
cytoplasm indicating that an additional pool of NPM 
cycles through different cellular compartments[37]. 
Surprisingly, we found that the localization of ARF to 
the nucleolus is exquisitely sensitive to constitutive 
AKT activity and redistributes ARF to the nucleoplasm 
in NPM-WT expressing cells, whereas ARF remains 
nucleolar and stable in the presence of NPM-S48A (Fig. 
2C and 2D). To further validate this as an oncogenically 
driven event, we co-expressed K-RasV12 to constitutively 
activate endogenous AKT and see a similar Ser48 
dependent ARF localization (Fig. S2A). Taken together 
these results suggest that nucleolar localization of both 
ARF and NPM are disrupted by AKT phosphorylation 
of NPM-Ser48, but that a stable pool of NPM persists in 
oligomeric form. We interpret this as an inability of AKT 
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to target oligomeric NPM due to Ser48 inaccessibility 
in the pentameric ring, but also that the cycling pool of 
NPM can be phosphorylated and prevented from forming 
pentamers, which prevents NPM:ARF sequestration rather 
than disrupting localization. 
In order to investigate whether AKT also regulates 
ARF localization in human tumor cells we examined ARF 
localization in T24 cells, a bladder cancer cell line which 
has elevated ARF expression [35] and constitutive AKT 
activity due to H-RasV12 mutation. In T24 cells, where 
NPM is phosphorylated on Ser48 (Fig. 1D), inhibition 
of AKT decreases the monomeric fraction of NPM (Fig. 
S2B) and increases NPM oligomers (Fig. S7B). This is 
also characterized by a change in the localization of 
phospho-S48-NPM, with the untreated cells showing a 
nuclear (non-nucleolar) and cytoplasmic localization, that 
is greatly reduced following AKT inhibition (Fig. S2C 
and S8D). In tumor cells with constitutive AKT activity, 
ARF displays a diffuse nucleoplasmic staining similar to 
Npm-/- MEFs or Npm-/- MEF reconstituted with NPM-S48E 
(Fig. 3A and 3B). Exogenous expression of NPM-S48A 
promotes ARF nucleolar foci and this is not observed with 
NPM-WT (Fig. 3A), due to endogenous AKT activity. 
To confirm that AKT was responsible for regulating ARF 
Fig.2: Phosphorylation of NPM-Ser48 regulates the localization of NPM and p19A. (A) Npm-/-, p53-/-double null MEF 
were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. 
Cells were fixed and stained with DAPI and anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates and 
whole cell lysates from Npm-/-;p53-/- MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, 
quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm-/-, p53-/-double null MEF were infected with 
pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed 
and stained with DAPI, anti-NPM and anti p19ARF.
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localization, we next inhibited AKT activity with PI-
103 or the pan-AKT inhibitor MK-2206. Both inhibitors 
promoted almost complete relocalization of endogenous 
ARF to the nucleoli (Fig. 3B). 
We additionally depleted AKT by siRNA and 
observed ARF nucleolar foci in an analogous manner 
to treatment with PI-103 or MK-2206 (Fig. S3A). 
Despite a more pronounced effect of myr-AKT1 on 
NPM oligomerization (Fig. 1F), depletion of AKT1 
or AKT2 appear to regulate ARF foci formation to a 
similar extent. This suggests that there may be functional 
redundancy between AKT isoforms towards NPM-Ser48, 
at least in T24 cells, or that AKT2 may be involved in the 
stabilization of AKT1 protein levels (Fig. S3A, western 
blots). Furthermore, the re-localization of ARF to the 
nucleolus following inhibition of AKT with MK-2206 
is characteristically observed where AKT is active, e.g. 
RASV12 mutated cell lines such as H1299 (Fig. S3B).
NPM mediated sequestration of ARF to the 
nucleolus is reported to increase ARF protein stability by 
preventing ubiquitin mediated degradation [38, 40, 43, 44, 
57]. We therefore addressed whether ubiquitination of ARF 
was affected by inhibition of AKT. Following inhibition 
of AKT, sequestration of ARF to the nucleolus correlated 
Fig.3: Inhibition of AKT promotes the stabilization and re-localisation of p14ARF to the nucleolus. (A) T24 cells were 
transfected with empty vector (control), FLAG-NPM or FLAG-NPM-S48A or (B) treated with DMSO, PI-103 (0.4 μM), or MK-2206 
(5 μM) for 24 hrs. Cells were fixed and stained with anti-NPM (red) and anti-p14ARF (green). Each graph represents the quantification 
of p14ARF staining intensity in the nucleolus and was performed by In Cell Analyzer 1000 automated epifluorescence microscope. Data 
are represented as mean ± SEM. (C) Ubiquinitation assay of p14ARF in H1299 cells transfected with Myc-tagged ubiquitin treated with 
DMSO, MG-132 (10 μM, 16 hrs) or MK-2206 (5 μM) for the times indicated.
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with enhanced co-migration of ARF with oligomeric NPM 
in semi-native gel electrophoresis (Fig. S2B), reduced 
ARF ubiquitination and higher ARF levels in whole cell 
lysates (Fig. S3C). The increased ARF levels following 
inhibition of AKT are not due to increased transcription 
as ARF mRNA levels are unchanged following inhibitor 
treatment (Fig. S3C). Therefore, we can conclude that 
elevated AKT activity restricts ARF accumulation at the 
nucleolus.
AKT promotes the inhibition of MDM2 through a 
nucleoplasmic NPM/ARF complex
The data presented above argues that 
phosphorylation of NPM-Ser48 by AKT promotes the 
nucleoplasmic localization of ARF. The major described 
function of ARF in cells is as an inhibitor of the E3 
ubiquitin ligase MDM2 and consequently leading to 
increased p53 stability [18, 21, 22]. The NPM mediated 
sequestration of ARF in the nucleolus has been proposed 
to increase MDM2 activity in the nucleoplasm[41] and 
furthermore, relocalization of ARF from the nucleolus 
to the nucleoplasm is associated with the increased 
formation of ARF/MDM2 complexes [45]. In T24 cells 
MDM2 is predominately detected in the nucleoplasm 
(Fig. S3D & S3E), in agreement with previous reports 
[47]. Although we observed an increase in ARF nucleolar 
localization following AKT inhibition, we did not detect 
any alteration in the cellular distribution of MDM2 (Fig. 
S3E) suggesting that although NPM and ARF traffic to the 
nucleolus following inhibition of AKT, MDM2 does not. 
MDM2 is known to be targeted to the nucleus in response 
to direct AKT phosphorylation of Ser166 and Ser186, 
explaining the nuclear localization that we observe in the 
RasV12 mutant T24 cells (Fig. S3D, S3E & S3F). However, 
expression of phospho-mimetic MDM2-S166D:S186D 
(MDM2-DD), that constitutively localizes in the nucleus 
of T24 cells, shows a similar MDM2 distribution and did 
not influence the nucleolar localization pattern of ARF 
upon AKT inhibition (Fig. S3F). In line with previous 
studies, we observe MDM2 activity is positively regulated 
by AKT but we find that this is influenced by the presence 
or absence of ARF (Fig. S3G). Taken together this 
suggests that NPM constitutively associates with ARF and 
cycles between a heterodimer organization in the nucleus 
and an oligomeric state that associates with the nucleolus. 
We can also assume that AKT promotes MDM2 nuclear 
localisation, but that its activity is controlled by the AKT 
mediated NPM-ARF nucleoplasmic pool once there.
In order to investigate whether a NPM/ARF 
nucleoplasmic complex is responsible for inhibition of 
MDM2, we performed large-scale stepwise purification 
of ARF from HeLa nuclear lysates and identified a high 
molecular weight complex that elutes after consecutive 
fractionations (ion exchange and size exclusion separation 
columns) containing both NPM and MDM2 in a highly 
Fig.4: Inhibition of AKT promotes enhanced MDM2 
activity via the increased association between NPM and 
p14ARF. (A) Npm-/-, p53-/-double null MEF were infected 
with pBABE retrovirus empty vector and pBABE expressing 
FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. 
Immunopurification of NPM was done by pulling down with the 
Flag tag (middle panel) followed by elution of complexes by the 
Flag peptide and subsequent immunopurification of endogenous 
MDM2 (lower panel). (B) Nuclear immunoprecipitates of 
MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). 
Immunoprecipitates and lysates were blotted with the indicated 
antibodies. (C) T24 cells were treated with MK-2206 (5 μM) 
as indicated. p14ARF was immunoprecipitated from whole cell 
lysates and nuclear extracts and the association with NPM and 
MDM2 determined by western blot. Immunoprecipitates and 
lysates were blotted with the indicated antibodies. (D) MDM2 
and (E) p53 ubiquinitation assay in H1299 cells transfected with 
wild type p53, HA-tagged ubiquitin and treated for 16 hrs with 
DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. 
Immunoprecipitates and whole cell lysates were probed with the 
indicated antibodies.
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purified protein fraction, indicating a strong molecular 
interaction between the constituents of the complex 
(lower MonoQ fractions A11 & A12, Fig. S4A). As AKT 
inhibition does not appear to influence the nucleoplasmic/
nucleolar distribution of MDM2 (Fig. S3D and S3E), this 
would suggest that MDM2 is not retained in the NPM/
ARF complex upon oligomerisation and therefore cannot 
stably associate with ARF positive nucleolar foci. This 
implies that AKT phosphorylation does not influence the 
ability of nucleoplasmic (monomeric) NPM to associate 
with ARF and MDM2 per se, but prevents oligomerisation 
of NPM which can accommodate ARF but not MDM2. 
To first confirm that a tripartite NPM/ARF/MDM2 
complex exists in the soluble non-nucleolar fraction, 
a two-step co-immunoprecipitation was performed of 
FLAG labelled NPM-WT, S48A and S48E from Npm-/- 
MEFs lysates. NPM complexes were eluted using FLAG 
peptide and subsequent NPM-MDM2 complexes isolated 
by immunoprecipitation of endogenous MDM2 from 
the FLAG elute. The presence of ARF in NPM-MDM2 
complex pool reveals that a tripartite complex exists and, 
although differential stability of the Flag-NPM derivatives 
make comparisons of levels difficult, this appears 
independent of the AKT mediated phosphorylation (Fig. 
4A). Next we wanted to determine whether the effect of 
AKT phosphorylation on NPM oligomer formation and 
ARF localisation affects the ability of NPM-ARF to 
associate with MDM2. In T24 cells we find an endogenous 
association of MDM2 with ARF (Fig. 4B and 4C) and 
also correlates with the low levels of basal MDM2 auto-
ubiquitin ligase activity (Fig. 4D). Upon inhibition of 
AKT with either PI-103 or MK-2206 we observe that 
the composition of the ARF complexes shifts to exclude 
MDM2 with a concomitant increase in the apparent 
association of NPM with ARF due to higher stability 
(Fig. 4C and S4B). Loss of MDM2 from the NPM/ARF 
complex was concurrent with incorporation of NPM into 
oligomers within the nucleolus and accumulation of ARF 
nucleolar foci (Fig. 3B, 4B and 4C). 
As mentioned above, basal MDM2 activity is 
restricted in T24 cells and as such we observe low 
background auto-activity or targeting of p53 (Fig. 4D 
and 4E). Inhibition of AKT and, associated restriction 
of ARF to the nucleolus, is associated with increased 
MDM2 auto-ubiquitination and MDM2 mediated 
(Nutlin3A sensitive) substrate targeting of wild type p53 
(Fig. 4D and 4E). Taken together, these results suggest 
that AKT phosphorylation disrupts NPM oligomerisation 
and controls MDM2 activity through the restricted 
compartmentalization of ARF at the nucleolus. 
Inhibition of AKT decreases p53mut stability in a 
NPM and ARF dependent manner
Since inhibition of AKT promotes ARF localization 
to the nucleolus and enhanced MDM2 activity, we wished 
to address what effect increased MDM2 activity has on 
endogenous p53. Upon inhibition of AKT we observe 
a decrease in the level of endogenous p53 in T24 cells 
(Fig. 4B). We were particularly intrigued as T24 cells 
express p53mut (in-frame deletion of Tyr126). Since 
MDM2 can degrade p53mut in-vivo [27], we hypothesized 
that constitutive AKT activity may contribute to enhanced 
p53mut stability via the phospho-S48-NPM dependent 
localization of ARF to the nucleoplasm and subsequent 
MDM2 inhibition. Immunofluorescence using a specific 
antibody (OP-29) that only recognises p53mut in the 
native conformation revealed a substantial decrease in 
p53mut staining following inhibition of AKT in T24 and 
PSN1 cells (RasV12; p53mut) (Fig. 5A). The reduction 
of p53 expression following AKT inhibition is not 
transcriptionally mediated as the levels of p53 mRNA 
do not significantly change following inhibitor treatment 
(Fig. S3C). In order to confirm that inhibition of AKT was 
directly modifying p53mut turnover, we examined p53mut 
stability following the addition of cyclohexamide in cells 
that were pretreated with or without MK-2206 for 24 
hrs (to allow ARF nucleolar localization). In MK-2206 
treated cells, the initial level of p53mut is lower compared 
to controls (Quant ratio = 0.4,* in Fig. 5B) and the half-
life of p53mut is reduced compared to controls, indicating 
that p53mut turnover is accelerated following inhibition of 
AKT (Fig. 5B). Similar results were also obtained using 
S35 Met/Cys pulse chase analysis (Fig. S5A). Furthermore, 
the effects of AKT inhibition appear to be specific to 
AKT and not due to downstream signaling targets as 
we do not observe any alterations to p53mut stability 
following treatment with the m-TOR inhibitor CC1-229 
(Fig. S5B). In order to extend these observations to other 
p53mut variants, we examined the ubiquitination of two 
p53 mutants with common hotspot mutations (R175H & 
R248W). Following AKT inhibition the ubiquitination 
of both p53R175H and p53R248W is enhanced, indicative of 
increased MDM2 activity (Fig. 5C).
AKT has been reported to phosphorylate and 
activate MDM2 leading to de-stabilization of p53 [58, 
59]. Similarly we find that inhibition of AKT in ARF null 
MCF7 cells leads to the stabilization of p53 (Fig. S3G). 
However, re-expression of ARF appears to be dominant 
over AKT mediated control of MDM2 activity (Fig. S3G). 
To assess if inhibition of AKT and regulation of ARF 
localization represented a general mechanism of regulating 
p53mut stability we examined p53 expression in a range of 
cell lines from different histopathological origins, with 
wild type and p53 mutations, following treatment with 
PI-103. Short term treatment with PI-103 reduces the 
levels of phospho-S48-NPM and is accompanied with a 
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rapid decrease of p53 levels in SQ20B (Fig. S5C). After 
16 hr exposure to PI-103 a reduction in p53 stability is 
seen in all cells except ARF null A549, PANC1 and ARF 
methylated Lovo cells (Fig. S5C and 6D).
In order to confirm that NPM oligomerisation 
was regulating p53mut stability we reasoned that direct 
perturbation of NPM oligomers should therefore regulate 
p53mut stability in an analogous manner to phosphorylation 
by AKT. NSC348884 is a compound that directly prevents 
formation of NPM oligomers [60] and treatment with this 
compound abrogated the effects of AKT inhibition or 
siRNA mediated knockdown of AKT on p53mut levels (Fig. 
5D and 5E). Moreover, the stability of p53 was reduced 
by siARF and promoted by the MDM2 inhibitor Nutlin3A 
Fig.5: Inhibition of AKT decreases p53mut stability. (A) T24 cells and PSN1 cells were treated with MK-2206 (5 μM) or DMSO 
for 24 hrs. Cells were fixed and stained with DAPI and anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) 
or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) 
or DMSO for the times indicated. Nuclear extracts were prepared from treated cells and blotted with the indicated antibodies. Quantification 
is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. 
(C) H1299 cells were transfected with HA-tagged-ubiquitin and mutant p53 (R175H or R248W) as indicated. Transfected cells were treated 
with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates and whole cell lysates were probed with 
the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA and treated with DMSO, MK-2206 
(5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-
targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole 
cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ 
and KRASG12D p53R172H ARF-/- pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5µM) or DMSO as indicated. Whole 
cell lysates were probed with the indicated antibodies.
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independently of NSC34884 (Fig. 5E). Conversely, Npm-
/-:p53-/- MEFs transfected with NPM-WT and p53R248H 
display increased stability of p53 upon expression Myr-
AKT1 (Fig. S5D). On the other hand, basal p53R248H 
levels appear more stable in the context of NPM-S48A, 
and importantly are not sensitive to myr-AKT (Fig. S5D). 
These findings suggest that disruption of NPM quaternary 
structure is sufficient to stabilize p53mut and functions 
upstream of both ARF and MDM2.
To ultimately confirm a positive role for AKT 
on p53mut stability we took advantage of pancreatic 
tumor cell-lines derived from the KRasG12 Pdx1-cre, 
p53R172H (KPC) mouse models of pancreatic ductal 
adenocarcinoma. We derived tumor cells from KPC 
(KRasG12D: p53R172H), Trp53flox (KRasG12D: p53fl), and 
ARF-/- (KRasG12D: p53R172H:ARF-/-) mice which have been 
described previously [21, 29, 61-63]. The individual cell 
lines show similar growth and survival metrics (Fig. S5E) 
but p53mut protein is clearly only stabilized in the presence 
of ARF (Fig. 5F). Furthermore, our results indicate that 
p53mut is degraded by MDM2 as Nutlin3A treatment 
stabilizes protein levels both in the presence and absence 
of ARF (Fig. 5F, lower panels), implying that constitutive 
MDM2 activity in the absence of ARF keeps p53mut levels 
low. 
Inhibition of AKT relieves the p53mut suppression 
of p73 
The data presented above suggests that inhibition 
of AKT promotes increased turnover of p53mut. Inhibiting 
p53mut function is of particular interest as mutations in 
p53 are attributed with gain of function phenotypes 
that accelerate tumor development, promote increased 
metastasis and resistance to therapy [24, 25]. Mutations 
in p53 mediate resistance to DNA damage induced by 
ionizing radiation (IR) [64] and therefore if our model 
is correct, AKT inhibition should revert this effect. 
Upon treatment with PI-103, the initial high levels of 
p53mut protein in T24 and SQ20B cell lines are reduced 
concomitantly with decreased phospho-S48-NPM and 
increased sensitivity to IR (Fig. S6A and S6B) in line 
with previous reports [65]. Moreover reduction of p53mut 
independently of AKT inhibition, via siRNA mediated 
silencing of p53, increases the sensitivity of T24 cells to 
IR (Fig. S6C). Inhibition of AKT with MK-2206 mediates 
reduction in p53mut and clonogenic survival upon exposure 
to IR (Fig. 6A), suggesting that the mechanistic regulation 
of NPM dynamics and ARF localization correlates with 
therapeutic resistance to DNA damage. Furthermore 
siRNA mediated knockdown of ARF expression similarly 
increased the sensitivity of T24 cells to IR, indicating that 
ARF promotes resistance to IR in p53mut T24 cells (Fig. 
6B). Nucleoplasmic ARF is targeted for degradation by 
the E3-ligase ULF [57], therefore manipulation of ULF 
levels should have the opposite effect on sensitivity to 
IR. Indeed, depletion of ULF resulted in elevated ARF 
levels and enhanced resistance of T24 cells to IR in an 
ARF dependent manner (Fig. S6D). To confirm that 
phospho-S48-NPM is responsible for IR resistance, we 
next ablated NPM expression in T24 cells and expressed 
siRNA resistant NPM and NPM-S48A mutants. In 
agreement with our model, overexpression of NPM-S48A 
increases ARF nucleolar foci (Fig. 6C, bars) and decreases 
clonogenic survival (Fig. 6C). These results suggest that 
AKT mediated phosphorylation of NPM-Ser48 promotes 
cellular resistance to IR by promoting ARF relocalization 
to the nucleoplasm and the stabilization of p53mut.
A classical gain of function phenotype associated 
with p53mut is the inhibition of the p53 family member 
p73 [24, 25]. As p73 shares many transcriptional targets 
with p53, activation of p73 following DNA damage can be 
inhibited by high stable levels of p53mut through dominant 
negative suppression of classical p53 targets [66, 67]. 
Therefore we reasoned that the increased sensitivity to 
IR following reduction in p53mut stability may be due to 
derepression of p73 function. Intriguingly, treatment of 
T24 or DLD1 p53mut cell lines with AKT inhibitors, PI-
103 or MK-2206 leads to the induction of p53/p73 target 
genes, p21 and BAX (Fig. 6D, 6E and S6E). Furthermore, 
the transcription of p21 in T24 cells is p73 dependent as 
siRNA mediated silencing of p73 expression significantly 
inhibited p21 expression (Fig. 6E and S6E). The induction 
of p21 was accompanied with a G1/S cell cycle arrest 
(Fig. S6F) and the induction of cellular senescence 
markers (β-galactosidase) (Fig. S6G). Moreover, the 
induction of senescence following IR was significantly 
increased in cells that were pre-treated with MK-2206 
(Fig. 6G). The observations were further confirmed in 
the KPC derived pancreatic cancer cells described above. 
Clonogenic assays show increased sensitivity of the KPC.
p53R172H (ARF+ve) cells to combination of AKT inhibition 
and IR, which is not exhibited by the KPC.p53fl or KPC.
p53R172H:ARF-/- cells (Fig. 6F). Interestingly we also see 
that tumor 3D spheroid growth of KPC.p53R172H (ARF+ve) 
cells are resistant to IR but become sensitive to treatment 
following AKT inhibition (Figure 6G), further confirming 
our hypothesis. Overall the data suggests that inhibition 
of AKT derepresses p53/p73 target genes which in turn 
restore the normal cellular response to DNA damage.
Inhibition of AKT represses p53mut stability in-vivo 
and sensitizes PSN1 xenografts to IR
The data presented suggests that the modulation 
of NPM quaternary structure through inhibition of AKT 
regulates ARF localization and p53mut stability in cell-
culture assays. This is turn mediates resistance to IR. 
We therefore wished to extend these observations in 
order to determine if inhibition of AKT could modulate 
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Fig.6: p14ARF has oncogenic activity in p53mut cells. (A) Clonogenic survival of T24 cells following treatment with ionizing 
radiation at the indicated doses. Cells were pre-treated with MK-2206 (5 μM) or DMSO before irradiation. Whole cell lysates were blotted 
with the indicated antibodies. (B) As in (A) except cells were transfected with non-targeting (NT) control or p14ARF siRNA before 
irradiation. Whole cell lysates were blotted with the indicated antibodies. (C) As in (A) except T24 cells were transfected with NT or 
NPM siRNA and siRNA resistant FLAG-NPMWT or FLAG-NPM-S48A as indicated. Whole cell lysates were blotted with the indicated 
antibodies. Right, quantification of p14ARF nuclear fluorescence by In Cell Analyser 1000 automated epifluorescence microscope. Data 
are represented as mean ± SEM. (D) T24 cells (p53Mut) and DLD1 cells (p53Mut) were treated with PI-103 (0.4 μM) for the indicated 
times. Bars indicate relative level of p53 at 8 Hr. Whole cell lysates were blotted with the indicated antibodies.(E) T24 cells transfected 
with NT or p73 siRNA against p73 were treated with PI-103 (0.4 μM) for 16 hrs. Whole cell lysates were blotted with the indicated 
antibodies. (F) Clonogenic survival of KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ and KRASG12D p53R172H 
ARF-/- pancreatic tumor cells following treatment with radiation at the indicated doses. Cells were pre-treated with MK-2206 (1µM) or 
DMSO before irradiation. (G) Bars showing 3D clonogenic survival of KPC mice derived KRASG12D p53Fl, KRASG12D p53R172H ARF+/+ 
and KRASG12D p53R172H ARF-/- pancreatic tumor cells following treatment with 6Gy radiation. Cells were pre-treated with MK-2206 (1µM) 
before radiation. Lower panel shows representative images of 3D colonies.
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p53mut stability and responses to IR in-vivo. To determine 
whether phospho-S48-NPM affects p53mut levels in-vivo, 
we stained serial sections of SQ20B xenografts from 
mice treated with either DMSO or PI-103 and observed 
decreased phospho-S48-NPM positivity and reduced 
levels of p53mut in PI-103 treated animals (Fig. S7A). 
However, overall tumor growth upon treatment with PI-
103 was not grossly affected [68]. As p53mut accelerates 
the development of pancreatic cancer [69], we extended 
these findings by utilizing a pancreatic PSN1 xenograft 
model which includes stromal support to appropriately 
replicate the human disease [70]. 
We confirmed that the regulation of NPM 
oligomerisation and p53mut levels in PSN1 cells were 
affected by AKT inhibition with MK-2206 in-vitro (Fig. 
5A, S5B and 7B). PSN1 cells were injected into athymic 
nude mice which were subsequently treated with MK-
2206 or carrier as indicated (Fig. 7A). Tumors were 
excised and reduced levels of phospho-S473-AKT and 
phospho-S48-NPM are apparent in the tumor lysates of 
Fig.7: Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor 
growth. (A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were 
treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or β-cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed and lysates 
probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 
(60 mg/kg). (B) Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). (C) 
PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts 
treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-
NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two 
alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) and tumor volumes 
measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3.
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MK-2206 treated mice, correlating with the enhanced 
oligomerization of NPM and induction of p21 expression 
(Fig. 7A). Additionally, we verified that increased p21 
expression in MK-2206 treated PSN1 xenografts was 
linked to inhibition of AKT, decreased phospho-S48-
NPM, ARF nucleolar re-localization and decreased p53mut 
expression by ex-vivo staining of tumor sections by 
immunofluorescence and immunohistochemical staining 
(IHC) (Fig. 7B, 7C and 7D). In agreement with previous 
reports [9], PI-3K and AKT inhibitors have little effect on 
tumor growth as single agents (Fig. S7C). However, our 
data demonstrates that reduction of p53mut levels reinstates 
tumor suppressor and DNA damage responses (Fig. 6A, 
S6A and S6B). We therefore selected the minimal dose 
that reduced AKT activity (60 mg/kg) for xenograft studies 
in combination with a single dose of IR (6 Gy, XRT) to 
determine whether synergy can be achieved in-vivo. MK-
2006 induced a tumor growth delay of 3.3 days compared 
to control animals, however, overall survival (time to 
sacrifice) was not affected. In contrast, the combination of 
MK-2206 with a single dose of XRT resulted in a growth 
delay of 12.5 and 9.2 days compared to either XRT or MK-
2206 alone (Fig. 7E and S7D). Moreover, this resulted in 
a significant increase in survival of the treated animals 
(represented here by the surrogate measure of 4 times 
tumor volume from time of randomization and initiation 
of treatment) compared to controls (p<0.0001 Mantel Cox 
Log-Rank; p<0.0001 Gehan-Breslow-Wilcoxon ). 
Phospho-S48-NPM is prevalent in human tumors
Having established that the phosphorylation of 
NPM-Ser48 by AKT promotes ARF nucleoplasmic 
localization, MDM2 inhibition and the stabilization of 
p53mut, we next wished to address if phosphorylation of 
NPM-Ser48 was a common phenomenon, and potentially 
contributing to the stabilization of p53mut in human tumors. 
We addressed the levels of phospho-S48-NPM by IHC 
staining of tumors from tissue samples (pancreas, lung, 
colon and breast) that frequently activate the EGFR/RAS/
PI-3K pathway. In addition, we also included cervical 
tumors as human papillomavirus (HPV) infected tissue 
that both overexpresses NPM and display elevated AKT 
activity [71], suggesting that this tumor material would 
serve as an additional control for elevated phospho-S48-
NPM expression. We detected phospho-S48-NPM in 
tumor material that was reduced by a blocking peptide 
and was non-concordant with total NPM (Fig. S8A & 
S8B). Tissue sections from pancreas, lung, cervix, colon 
& breast stained positive in greater than 50% cases 
and were scored as low, medium or high depending on 
reactivity to the pS48-NPM antibody (Fig. 8A and Table 
S1). This data together with the cell line analysis (Fig. 
S5C) suggests that NPM quaternary structure is perturbed 
in a variety of human tumors. The oncogenic disruption 
of NPM is likely to disrupt additional signaling pathways 
which may promote tumorigenesis in p53 null or p53 
inactivated tumors (e.g. cervical cancer), [36, 37] but the 
increased stability of p53mut is increasingly observed to 
be prognostic in breast cancer [72]. EGFR/HER2+ve and 
ERα+ve breast cancers have previously been described to 
have elevated AKT activity [73, 74], we therefore aimed to 
correlate phospho-S48-NPM staining, with EGFR/HER2 
positivity, p53 staining and tumor stage. Interestingly, the 
highest levels of p53mut segregated with advanced tumor 
stage and the degree of phospho-S48-NPM staining 
correlated with EGFR/HER2 positivity and increased 
p53 staining intensity indicative of p53mut (Fig. 8B and 
S8C). Not all EGFR/HER2+ve and ERα+ve breast cancers 
have p53mut, however the coalescence of both mutations 
appears to promote advanced stage disease [75]. Our 
results suggest that AKT contributes to this effect by 
stabilizing p53mut protein, however, previous reports 
indicate that AKT reduces p53 levels via nuclear targeting 
of MDM2. To confirm whether these correlations are 
due to the presence of ARF we examined AKT activity 
and p53 levels in a large cohort of invasive breast cancer 
where ARF expression is known (The Cancer Genome 
Atlas, TCGA, http://cancergenome.nih.gov/). We find 
that p53 protein levels negatively correlate with increased 
AKT activity, but only in tumors where the CDKN2A 
transcript is detectable above background (values in green, 
Table S2). Importantly the negative correlation is lost in 
tumors where CDKN2A is expressed (therefore likely to 
be ARF positive) or when mutations in TP53 have been 
annotated (Table S2). To robustly test AKT activity we 
examined levels of the AKT substrate pRas40, which is 
used to monitor AKT activity in patients treated with MK-
2206 [10]. We first confirmed that AKT activity correlates 
with substrate phosphorylation, and found AKT substrate 
activity has an overall positive correlation with total p53 
levels (values in red,Table S2). Furthermore, we find that 
this positive correlation can be found for both p53WT and 
p53mut tumors, but is restricted to cases where CDKN2A 
transcript is detectable above background. Importantly, 
the positive correlation is lost in the absence of CDKN2A 
message (i.e. ARF-ve) (Table S2). This supports previous 
data on AKT mediated targeting of MDM2 and our 
current observations, as AKT can promote either negative 
or positive regulation of p53 depending on the presence 
of ARF and its ability to restrict MDM2 activity in the 
nucleoplasm (Fig. S8F). 
The pancreatic TMA indicated 50% phospho-S48-
NPM positivity despite a propensity for all pancreatic 
tumors to harbor activating RAS mutations (Fig. 8A). 
Activating mutations occur at residues G12-, G13- or Q61-
KRAS and result in a range of amino acid substitutions 
that can differ in the effector pathway and/or potency of 
activation [76]. Not surprisingly, AKT activity has been 
described to vary in pancreatic tumors [77]. To address 
the correlations between AKT substrate activity and p53 
levels, we obtained a fresh pancreatic TMA and confirmed 
Oncotarget6155www.impactjournals.com/oncotarget
the correlation between phospho-S48-NPM, p53 and AKT 
within this cohort (Fig. 8C). We also observe that 50% 
of the tumors to be in the lowest quartile of phospho-
S48-NPM staining and display low AKT, potentially 
indicating variations in PI3K activation by different 
mutations of RAS (Fig. 8C, left scatter plot). Importantly, 
total phospho-S48-NPM staining significantly correlates 
with active AKT (phospho-S473-AKT), with the highest 
correlation in the nuclear compartment (Fig. 8C). 
Interestingly, the ‘RXXS’ motif incorporating 
NPM-Ser48 lies within a characterized nuclear export 
sequence [55] (Fig. 1B) and a proportion of phospho-
Fig.8: Phospho-S48-NPM correlates with p53 levels in human tumors. (A) Tissue micro array sections (US Biomax) of 
both normal and tumor derived tissue from lung, pancreas, cervix, colon and breast were stained with pS48-NPM. All images are 5 x 
magnifications and scale bars represent 200 µm. Total numbers of samples analysed by automated Aperio scanning and those with low, 
medium or high degrees of staining are shown in Table 2. (B) (Left) Data from the breast tumor microarray demonstrating the degree 
of phospho-S48-NPM staining in those cores annotated as EGFR/HER2 positive (low and high) or estrogen receptor (ER) +ve. (Right) 
Phospho-S48-NPM staining in cores scored low, medium or high for p53. (C) Scatter plots demonstrating bivariate correlation of automated 
total pS48-NPM and nuclear phospho-S473-AKT staining in human pancreatic ductal adenocarcinomas (n=122, left), or cytoplasmic pS48-
NPM in samples with p53 positivity (n=81, right). Below, representative images for comparison of variation in pS48-NPMcyto scoring of 
pancreatic ductal adenocarcinoma tumor micro array sections.
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S48-NPM is cytoplasmic (Fig. 2A, Fig. S2C & S8D). We 
next restricted scoring to cytoplasmic positivity, solely 
within pancreatic ductal adenocarcinomas and scored for 
elevated p53 staining indicative of p53mut. Of the total 
122 tumors, 81 scored positive for p53 and the degree of 
p53 staining correlated with the levels of phospho-S48-
NPMcyto (<p=0.001) (Fig. 8C). As the INK4A/ARF locus 
can be deleted, methylated or transcriptionally repressed, 
we obtained mRNA from a subset of tumors for which 
material was available (40 tumors). We determined that 
26/40 pancreatic tumors were positive for ARF mRNA and 
observed a significant correlation between phospho-S48-
NPM and p53 staining intensity in tumors where ARF was 
expressed (Fig. S8E). 
Overall the data suggest that an AKT/NPM/ARF 
pathway contributes to the maintenance of elevated 
levels of p53mut. Thus, we can present a model (Fig. S8F) 
whereby NPM and ARF are constitutively associated in 
high molecular weight complexes at the nucleolus. AKT 
phosphorylation on Ser48 prevents NPM oligomerization, 
thereby increasing nucleoplasmic NPM/ARF that forms an 
inhibitory complex with MDM2 and results in increased 
p53mut stability. 
DISCUSSION
The data presented in this report describes how the 
stability and localization of ARF is regulated by NPM 
quaternary structure. Previous reports have demonstrated 
that the inhibition of NPM oligomerisation using small 
molecule inhibitors [60] or RNA aptameres [78] promotes 
the nucleoplasmic localization of NPM and ARF with 
accompanying activation of p53, but the physiological 
context was not known. We have found that AKT limits 
NPM oligomerisation (Fig. 1), which in turn restricts 
NPM nucleolar localization and accumulation of ARF at 
the nucleolus (Fig. 2 & 3). In tumor cells with constitutive 
activation of AKT and mutation of p53, the promotion 
of nucleoplasmic ARF/NPM leads to the subsequent 
stabilization of p53mut through inhibition of MDM2 (Fig. 
4 & 5). 
Although ARF has long been recognized as an 
inhibitor of MDM2 [21, 22], debate exists regarding the 
cellular location and mechanism of ARF mediated MDM2 
inhibition. ARF has been reported to promote p53 stability 
by sequestering MDM2 to the nucleolus [79, 80], whereas 
others have reported that nucleoplasmic ARF suppresses 
MDM2 activity [46-48, 81]. Our data argues for a model 
whereby MDM2 is inhibited by a nucleoplasmic pool of 
NPM associated ARF (Fig. 4 and 5). Oligomerisation of 
NPM promotes accumulation of ARF at the nucleolus but 
appears incompatible with MDM2 association (Fig. S2B 
and 4). In agreement with this model, overexpression of 
NPM and sequestration to the nucleolus has been proposed 
as mechanism whereby tumor cells inactivate and stabilize 
ARF [41, 48, 57, 81], 
NPM has also been reported to bind and stabilize 
p53 directly [82] and in addition, promote p53 stability by 
binding MDM2 [83]. Kurki et al. reported that following 
UV or viral stress, NPM re-localizes to the nucleoplasm 
from the nucleolus and is associated with MDM2, in 
an analogous manner to the increased formation of 
ARF/MDM2 complex [45]. In agreement, failure to 
re-localize NPM to the nucleoplasm prevents NPM 
mediated inhibition of MDM2 [84]. Our results suggest 
that inhibition of MDM2 by NPM and ARF are not 
independent and respond to cellular stress via disruption 
of NPM oligomerization. 
Although we have focused on the AKT mediated 
regulation of p53mut stability, the observation that 
regulation of NPM oligomerisation governs ARF 
localization may also be a direct mechanism which 
facilitates p53 stabilization following oncogene activation 
in the absence of DNA damage [19]. In the absence of 
additional mutations, oncogene activation leads to p53 
stabilization and the induction of cellular senescence. 
Furthermore, growing evidence suggests that AKT activity 
can mediate p53 stabilization and induction of senescence 
[85-87]. AKT is known to directly phosphorylate S166-
MDM2 leading to enhanced activity and reduced p53 
levels, which in agreement with previous studies where 
observations were made in cells with INK4a/ARF deletions 
[58, 59], we find AKT inhibition increases p53 levels in 
ARF null MCF7 cells (Fig. S3G). Importantly, we find 
that expression of ARF stabilizes p53 but is now subject 
to NPM mediated control and AKT inhibition decreases 
p53 levels. This is in line with emerging evidence where 
constitutive activation of AKT has been demonstrated 
to inhibit MDM2 activity [85]. Moreover, we find that 
correlations exist between AKT activity and p53 levels in 
breast and pancreatic cancer cohorts, and are dependent on 
CDKN2A expression levels (Table S2). This is a relevant 
point for the administration of AKT inhibitors in the clinic 
where efficacy is likely to rely on ARF status as well as 
p53mut. 
The induction of senescence following oncogene 
activation has been unequivocally demonstrated to 
require ARF [19-22]. However, our data and reports 
by others [41, 46-48, 81] suggest that the regulation of 
ARF cellular localization is also required for inhibition 
of MDM2. Recent studies have reported that the strength 
of signal originating from oncogene activation is also 
important in the ARF mediated activation of p53 [88-90]. 
As ARF localization depends on NPM oligomerisation this 
suggests that the strength of a signal must be sufficient 
to disrupt the equilibrium and release ARF, thereby 
creating a cellular sensor of stress or oncogene activation. 
We have demonstrated that phosphorylation of Ser48 by 
AKT contributes to this process, but additional residues 
of the N-terminal of NPM have been predicted in-silico 
to regulate oligomerisation [53]. Therefore, NPM may be 
able to integrate multiple signals from different kinases in 
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order to control ARF localization.
Approximately 40 % of human tumors have a 
missense mutation in p53 [91], but mutations alone do 
not account for the inherent stability of p53mut nor the 
heterogeneity of levels in tumor tissues [27, 29, 30, 92]. 
Since highly stable p53mut protein is considered oncogenic, 
it is important to identify the molecular mechanisms 
that contribute to p53mut stability, as they offer novel 
therapeutic routes to target tumors. 
Growing evidence suggests that since MDM2 
can mediate degradation of p53mut in normal tissue [27, 
92] the stabilization of p53mut is not due to the lack of 
transcriptional activation of MDM2. Therefore, the 
stabilization of p53mut is not due to loss of MDM2 but 
suppression of MDM2 activity which arises as cells 
become transformed. Therefore targeted therapies that 
re-engage MDM2 activity and destabilize p53mut have the 
potential to sensitize p53mut cells to therapy. In agreement 
with this approach tumor cells are often addicted to heat 
sock proteins (HSP) that promote p53mut stability. HSP not 
only directly stabilize p53mut, they also inhibit E3 ligases 
(MDM2 and CHIP) responsible for p53 ubiquitination. 
Treatment with the HSP90 inhibitor 17AAG or the 
HDAC6 inhibitor SAHA, releases MDM2 and p53mut 
from this HSP “cage” leading to the rapid destabilization 
of p53mut and the sensitization of p53mut tumor cells to 
chemotherapeutic agents [31, 32]. 
Our data indicates that in tumors where NPM 
is unable to oligomerize, retention of ARF expression 
contributes to the stabilization of p53mut cells. In these 
cases, treatment with AKT or PI-3K inhibitors reduces 
p53mut stability and sensitizes tumor cells to therapies that 
engage p73. MDM2 activity is absolutely required for 
this phenomenon as the MDM2 inhibitor Nutlin3A blocks 
p53mut turnover which is induced following inhibition of 
AKT (Fig. 5E). Furthermore, in our cohort of pancreatic 
tumors that retained ARF expression, the level of phospho-
S48-NPM significantly correlated with elevated detection 
of p53mut indicating than in certain tumors AKT and ARF 
contribute to the stabilization of p53mut (Fig. 8, Table S2). 
An interesting aspect of this study is that although 
ARF is a well characterized tumor suppressor [93] the 
observation that ARF contributes to the resistance against 
IR through stabilization of p53mut and inhibition of p73, 
suggests that in some circumstances ARF behaves as 
an oncogene. Interestingly other reports have suggested 
ARF has oncogenic activity than can affect tumor growth 
in a tissue specific manner [94, 95]. Independent of p53, 
human prostate tumors with PTEN loss show increased 
ARF expression which correlates with the increased 
aggressiveness of disease [95]. Furthermore, ARF has 
been shown to protect tumor cells from metabolic stress 
by promoting the induction of autophagy [94]. These 
reports argue that in specific tissues ARF can exert tumor 
promoting activity that is distinct from regulation of p53. 
However, our data and recent reports from others argue 
that an additional aspect of an oncogenic role for ARF is 
the maintenance of p53mut stability. Pml knockout mice 
on a p53mut background displayed stabilization of p53mut 
with expression of ARF, suggesting that loss of PML 
promotes oncogenic activation of ARF which in turn 
stabilizes p53mut through inhibition of MDM2 [28]. Further 
evidence for a role in ARF mediated stabilization of p53mut 
came from a study that demonstrated TGF-β1 induced 
destabilization of p53mut by inhibiting E2F-1 mediated 
transcription of ARF [96]. Interestingly, AKT has been 
demonstrated to increase ARF transcription by relieving 
BMI1 repression of ARF transcription [97] and therefore 
provides a potent mechanism to stabilize p53mut via the 
elevated transcription and nucleoplasmic localization of 
ARF. 
The EGFR/RAS/PI3K/AKT pathway has been 
widely linked with therapeutic resistance of tumors. 
Evidence from in-vitro and in-vivo models suggests 
that PI3K-AKT activation is associated with decreased 
sensitivity to several chemotherapeutic agents and 
radiotherapy [3, 7]. Additionally, clinical reports highlight 
the route of resistance to EGFR and HER2 targeted 
agents, Cetuximab and Trastuzumab (Herceptin), as being 
reversible upon PI3K-AKT inhibition [98, 99]. Our results 
describe one route of tumor initiation where pathway 
activation promotes oncogenic activity of p53mut. While 
this mutational cooperation may contribute to progression, 
it more importantly highlights the patient cohort where 
AKT inhibitors are most likely to display efficacy. 
The acquisition of p53 mutations, rather than 
deletion, can be a predictor of prognosis and is now 
included as a hallmark of cancer [24, 100]. Recently, 
genetic studies in mice have demonstrated that p53mut gain 
of function activity requires mutant K-Ras, thus confirming 
a genetic link [101]. We provide evidence for RAS/PI3K/
AKT mediated resistance of tumors being dependent on 
ARF and p53mut status and as such, a potential confounder 
of the efficacy in clinical trials. Together, our results 
outline how the genetic route of tumor initiation impacts 
on therapeutic responses and moreover, provides a patient 
selection strategy to ensure maximal therapeutic benefit of 
PI3K-AKT agents currently under clinical investigation.
MATERIALS AND METHODS
Cell culture and transfection
HT-1080-SG1 and SG2 tumor cell lines were 
kindly provided by Eric Stanbridge (Stanford, CA), 
AKT knockout MEF’s were kindly provided by Dr. 
Birnbaum (University of Pennsylvania PA). NPM-/-, p53-
/- and p53 -/- MEFs were kindly provided by Pier Paolo 
Pandolfi (Harvard, Boston MA). PSN1 cells were kindly 
provided by Thomas Brunner (University of Oxford) and 
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subsequently genotyped at the DDC laboratories, London, 
to confirm cell identity. The mutation data reflects the 
information on the COSMIC Cell Line Project database 
http://cancer.sanger.ac.uk/cancergenome/projects/
cell_lines/. All other cell lines were obtained from the 
American Type Culture Collection (ATCC). Cells were 
cultured in DMEM containing 4.5 g/l glucose (Invitrogen) 
supplemented with 10 % fetal bovine serum (Invitrogen), 
penicillin (100 units/ml), and streptomycin (100 mg/ml). 
All cultures were maintained at 37°C in water saturated 
5 % CO2 with the exception of MRC5 cells which were 
cultured at 37°C in 3 % O2/5 % CO2. Cells were plated to 
80 % confluence prior to siRNA transfection. Smartpool 
siRNA (Dharmacon) against NPM, p14ARF and AKT 
were used where indicated. Individual siRNA against 
NPM (ACAAGAAUCCUUCAAGAAA) was used 
in conjunction with re-expression of NPM constructs. 
sip73 sequences (GCAAGCAGCCCAUCAAGGA 
and GAGACGAGGACACGUACUA), sip53 
(GACUCCAGUGGUAAUCUAC), siULF 
(GGUAGUGACUCCACCCAUUUU). Cells were 
transfected with plasmid or siRNA (50 nM) construct 
using Lipofectamine 2000 (Invitrogen) or Dharmafect 
(Dharmacon) for 48 hours prior to drug treatment. Mutant 
p53 plasmids (R248W & R175H) cloned into pcDNA3 
vector backbone were a kind gift from Xin Lu (Ludwig 
Institute for Cancer Research, University of Oxford).
KPC mice derived cell lines
Pdx1-cre, KrasG12D, Trp53flox, Trp53R172H and 
ARF-/- mice have been described previously [21, 29, 61-
63] . Mice were kept in conventional animal facilities 
and experiments were carried out in compliance with UK 
Home Office guidelines. Genotyping was performed by 
Transnetyx (Cordova, TN, USA). Animals were monitored 
until showing symptoms of late stage pancreatic cancer 
and then sacrificed as per institutional guidelines. Tumor 
and metastatic burden was assessed by gross pathology 
and histology.
Tumor tissue for preparation of PDAC cell lines 
was harvested in DMEM.  Tumors were disaggregated by 
fine mincing with scalpels, and plated in growth media 
(Dulbecco’s modified Eagle medium containing 10% fetal 
bovine serum and 2mmol/L L-glutamine). Cells were 
allowed to adhere, washed, grown to confluence and then 
passaged as normal.
Chemicals and antibodies
All chemicals were purchased from Sigma Aldrich 
unless stated otherwise. PI-103 was purchased from 
Merck. CCI-779 was purchased from Sigma. MK-2206 
was purchased from ChemieTek. All inhibitors were 
dissolved as concentrated stock solutions in DMSO 
(1 mM) and stored at -80oC. Antibodies, anti-AKT1 
(#9272), anti-AKT2 (#2964), anti-AKT1 (#2938 ) anti-
phospho-Ser 473-AKT (#9721), anti-p44/42 MAPK 
(Erk1/2) (#137F5), anti-phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (#9106) and anti-phospho-S6 (Ser 
235/236) (#91B2) were purchased from Cell Signaling 
Technologies. Anti-GAPDH (2251-1) and anti-p73 
(1636-1) were purchased from Epitomics. Anti-HA tag 
(05-904) and anti-Myc tag (05-724) were purchased 
from Millipore. Anti-p14ARF (Ab11048 and Ab49166), 
anti-nucleophosmin (ab10530), anti-ULF (Ab80645), 
anti-Fibrillarin (Ab5821), anti-Lamin B1 (Ab16048) and 
anti-p53 (D01 clone) (Ab80645), were purchased from 
Abcam. Anti-p19ARF (NB-200-174) and anti-p14ARF (NB-
200-111) were purchased from Novus Biologicals. Anti-
FLAG (M2) was purchased from Agilent Technologies. 
Anti-actin (A4700) was purchased from Sigma. Anti-p21 
(sc6246), anti-MDM2 (SMP14 (Sc-965)), anti-HSP-90 
(Sc-69703) and anti-Bax (2D2) were purchased from 
Santa Cruz Biotechnology. The anti phospho-Ser48-NPM 
was raised against a synthetic peptide spanning residues 
45-56 of NPM (RTVSLGAGAKDE) incorporating 
phospho Ser (underlined) at position 48. Peptide synthesis 
and immunizations were carried out by Eurogentec. The 
anti phospho-Ser48-NPM used in this study was affinity 
purified against the phosphopeptide. Secondary antibodies 
anti-mouse and anti-rabbit HRP conjugates were purchased 
from Pierce and the Jackson Laboratory. Fluorescent 
tagged antibodies for use on the Licor Odyssey western 
blot imaging system were purchased from Licor and 
Invitrogen. Fluorescent conjugated secondary antibodies 
for immunofluorescence were purchased from Invitrogen. 
Protein biochemistry 
Preparation of cell lysates and western blot
Unless specified otherwise, whole cell lysates were 
prepared by lysing cells with 1% NP-40 lysis buffer (50 
mM Tris-HCl, 150 mM NaCl, 2 mM EGTA, 5 mM MgCl2, 
1 % (v/v) NP-40, 10 mM sodium β-glycerophosphate, 50 
mM NaF, 1 mM Na3VO4, 5 mM sodium pyrophosphate 
and ‘Complete’ proteinase inhibitor cocktail EDTA free 
(1 tablet/10 ml lysis buffer (Roche)). Lysates were rotated 
end over end for 30 min at 4ºC and centrifuged (20,817 x 
g, 10 min) before the addition of NuPage sample buffer 
or SDS-PAGE sample buffer (1x concentration, 62.5 mM 
Tris-HCl pH 6.8, 25 % (v/v) glycerol, 2 % (w/v) SDS, 0.01 
% (w/v) bromophenol blue). For immunoprecipitation, 
lysates were pre-cleared (4 ºC, 1 Hr) with protein-G 
coupled to magnetic beads (Millipore), prior to incubation 
with antibody conjugated to protein-G magnetic beads. 
Lysates and antibody coupled beads were rotated end over 
end at 4°C for at least 3 Hrs. Immunoprecipitates were 
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washed (4 x 1ml) with lysis buffer minus the protease 
and phosphatase inhibitors. Immunoprecipitated proteins 
were boiled in SDS-PAGE sample buffer for western blot 
analysis. 
Nuclear lysates were prepared as described 
previously [102] with additional modifications. Briefly, 
3-5 x 106 cells were trypsinised and harvested by 
centrifugation (500 x g, 5 min) , washed twice in TBS 
and re-suspended in 1-2 ml ice cold buffer A (10 mM 
HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 1 mM DTT, 0.5 mM PMSF) by gently pipetting 
in a 1 ml tip. The cells were left on ice for 15 min to 
swell, after which 75 µl of 10 % NP-40 was added. The 
tube was vigorously vortexed for 10 sec and centrifuged 
at 500 x g for 2 min. The supernatant, which constitutes 
the cytoplasmic fraction, was removed. The nuclear pellet 
was re-suspended in 150 µl ice-cold lysis buffer (150 
mM NaCl, 20 mM Hepes pH 7.5, 0.5 mM EDTA, 0.5% 
(v/v) NP-40, 10 mM sodium β-glycerophosphate, 50 mM 
NaF, 1 mM Na3VO4, 5 mM sodium pyrophosphate and 
‘Complete’ proteinase inhibitor cocktail EDTA free (1 
tablet/10 ml lysis buffer) and the sample sonicated. The 
nuclear extract was centrifuged (20,817 x g, 15 min, 40C) 
and the supernatant containing the nuclear extract was 
used as an in-put for immunoprecipitation or added to 
SDS-PAGE sample buffer as described above.
For western blot, samples were boiled (100 ºC, 
5 min) and proteins resolved on NuPage Bis-Tris gels 
(Invitrogen). Resolved proteins were transferred by 
western blot to PVDF (Millipore) or Nitrocellulose 
(Biorad) membrane and blocked in either 5% (w/v) non-
fat milk or 5 % (w/v) BSA dissolved in PBS, 0.1 % (v/v) 
Tween-20 prior to antibody addition. Those membranes 
probed for phosphorylated proteins were blocked in 5 
% (w/v) BSA, TBS (50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl), 0.1 % (v/v) Tween-20. Primary antibody detection 
was achieved with HRP conjugated secondary antibodies 
(Pierce) and exposure to X-Ray film (Kodak). For blots 
which were quantified, samples were run by western 
blot and transferred onto Nitrocellulose membrane 
(Biorad). Membranes were blocked in Licor blocking 
buffer and incubated with primary antibody overnight 
followed by incubation with fluorescently conjugated 
secondary antibodies. Membranes were scanned on 
the Licor Odyssey infrared scanner and signal intensity 
determined using the Odyssey software (V3.0). Signals 
were normalized to GAPDH as a loading control. All 
quantification was done on the same nitrocellulose 
membrane without stripping. 
In-Vitro Kinase assay
Endogenous AKT was immunoprecipitated 
from T24 cells, glycine eluted and combined with 
immunoprecipitated HA-NPM, HA-NPM-S48A or anti 
HA-IP from non-transfected cells as indicated in 1 x 
kinase buffer (Cell Signaling). The reaction was incubated 
with cold ATP (20 µM) and radio-labeled gamma 32P 
ATP (2 µM) at 37°C. The reaction was heat inactivated 
in the presence of denaturing SDS-PAGE sample buffer, 
separated by SDS-PAGE, western blotted and exposed to 
a phosphor screen. The membrane was additionally probed 
by standard western blot. 
Ubiquinitation assays
H1299 cells (1 x 106) were transfected with pcDNA3 
expressing either HA-tagged Ubiquitin or Myc-tagged 
Ubiquitin (10 µg) alone or in combination with pcDNA3 
expressing p53Wt (10 µg) or the p53 mutants R175H or 
R248W (10 µg) using Lipofectamine 2000 (Invitrogen). 24 
hrs following transfection cells were treated with 10 µM 
MG-132, 5 µM MK-2206 or 5 µM Nutlin3A as indicated 
in the figure legends. Cells were washed twice with PBS 
and lysed by scrapping in ice cold RIPA buffer (50 mM 
Tris pH 8.0, 150 mM NaCl, 1 % (v/v) Triton X 100, 0.5 
% (w/v) sodium deoxycholate, 0.1 % (w/v) SDS, 1 mM 
EDTA, 1 mM EGTA, 50 mM NaF, 1 mM Na3V04, 10 mM 
sodium β-glycerophosphate, 5 mM sodium pyrophosphate 
and ‘Complete’ proteinase inhibitor cocktail EDTA Free 
(1 tablet / 10ml lysis buffer) supplemented with 1 mM 
N-Ethylmaleimide. Lysates were rotated end over end 
(4ºC, 30 min), sonicated, centrifuged (20,817x g, 15 min, 
4ºC) and pre-cleared with protein G coupled to magnetic 
beads (Millipore). Pre-cleared lysates were incubated 
with the appropriate antibody conjugated to protein G for 
3 Hrs. Protein G beads were washed with 50 mM Tris pH 
8.0, 150 mM NaCl, 1 % (v/v) Triton-X-100, 0.5 % (w/v) 
sodium deoxycholate, 0.1 % (w/v) SDS before boiling in 
SDS-PAGE sample buffer. Samples were resolved on 10 
% NuPage Bis-Tris gels or 4-8 % Nupage Tris-Acetate 
gels (Invitrogen). 
Semi-native Gel Electrophoresis
Cells were washed twice with ice cold PBS and 
lysed by scrapping in ice cold lysis buffer (50 mM Tris 
pH 8.0, 150 mM NaCl, 1 % (v/v) Triton X 100, 1 mM 
EDTA, 1 mM EGTA, 50 mM NaF, 1 mM Na3V04, 10 mM 
sodium β-glycerophosphate, 5 mM sodium pyrophosphate 
and ‘Complete’ proteinase inhibitor cocktail EDTA Free 
(1 tablet / 10ml lysis buffer). Lysates were rotated end 
over end (4ºC, 30 min), centrifuged (21000 x g. 15 min), 
diluted in the appropriate volume of NuPage sample buffer 
(samples were not boiled) and immediately loaded onto 10 
% Bis-Tris Nupage gels or Native Nupage gels. Gels were 
run at a constant voltage (100 V) at 4ºC before transfer to 
Nitrocellulose membrane.
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Purification of p14ARF from HeLa Nuclear extracts
Fractionation of HeLa cells was performed as 
previously described [103]. Briefly, 20 grams of HeLa 
cell pellets (Cilbiotech, Mons, Belgium) were resuspended 
in 40 ml lysis buffer (20 mM Tris–HCl pH 7.4, 2.5 
mM MgCl2, 0.5 % (v/v) Nonidet P-40, 1 mM PMSF, 
1 mM DTT and 1 mg/ml each of aprotinin, pepstatin, 
chymostatin and leupeptin) and incubated on ice for 10 
min prior to centrifugation (1,300 × g, 4 min at 4°C). The 
supernatant containing cytoplasmic proteins was discarded 
and the remaining cell pellet was further resuspended in 
40 ml buffer containing 100 mM phosphate, pH 8.0, 0.5 
M KCl, 5 mM MgCl2, 1 mM EDTA, 0.75 % (v/v) Triton 
X-100, 10% (v/v) glycerol, 1 mM PMSF, 1 mM DTT and 
1 mg/ml each of aprotinin, pepstatin, chymostatin and 
leupeptin and the supernatant containing nuclear proteins 
was collected. The obtained extract was dialyzed against 
Buffer A (50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 5 % 
(v/v) glycerol, 1 mM DTT and 0.1 mM PMSF) containing 
50 mM KCl. The extract was applied to a 20 ml HiLoad 
Q Sepharose column (GE Healthcare). The column was 
washed in Buffer A containing 300 mM KCl and proteins 
bound to the column were eluted using a linear gradient of 
300-700 mM KCl. Fractions containing p14ARF (fractions 
B8-B2) were pooled, concentrated using Amicon Ultra 
Ultracel-3K filter units (Millipore) and separated on a 
Superdex 200 HR 10/30 column (GE Healthcare) in Buffer 
A containing 150 mM KCl. Fractions containing p14ARF 
were eluted as two separate pools of different molecular 
weight (pool I is represented by fractions B6-C1, pool II 
consists of fractions C4-C10) were pooled, the fractions 
in each pool were combined and further loaded separately 
onto a 1 ml MonoQ column (GE Healthcare) in Buffer 
A containing 150 mM KCl. The column was washed and 
bound proteins were eluted as described above for the 
HiLoad Q Sepharose column purification step. At each 
purification step, aliquots of the obtained fractions were 
analyzed by western blot for the presence of p14ARF using 
a specific antibody (Bethyl Laboratories, A300-340A). 
Fractions identified as containing p14ARF were pooled for 
the next chromatography step.
35S Met/Cys Pulse Chase 
T24 cells (1 x 106/10 cm dish) were plated 24 hrs 
before addition of MK-2206 (5 µM) or DMSO control and 
incubated for 18 Hrs. MK-2206 or DMSO was maintained 
in culture media throughout the experiment Cells were 
washed twice with Met/Cys free media (Invitrogen) 
and cultured for 1 hr at 37ºC with Met/Cys free media. 
Following depletion of intracellular Met/Cys stores, cells 
were incubated with Met/Cys free media supplemented 
with 200 µCi 35S Met/Cys (EasyTag™ EXPRESS35S 
Protein Labeling Mix 35S, PerkinElmer). Cells were 
metabolically labeled for 1 Hr before being washed twice 
with complete media containing unlabeled Met/Cys. 
Cells were chased for 30 min- 4 Hrs in complete media 
at 37ºC before being washed twice with PBS and lysed 
by scrapping in 1 % (v/v) NP-40 lysis buffer. p53 was 
immunoprecipitated as outlined above. Samples were run 
on a 10 % NuPage Bis Tris gel. Gels were dried before 
exposure to a phosphor screen. Additionally samples were 
probed by western blot. 
Immunofluorescence and Immunohistochemistry
For analysis of cells using the In Cell Analyzer 1000, 
automated epifluorescence microscope (GE Healthcare), 
cells were plated into 96-well plates at a density of 
10,000 cells/well and incubated overnight at 37°C with 
5% CO2 in a humidified incubator. Cells were exposed 
to inhibitor 24 hours prior to fixation. Cells were fixed 
with 4 % paraformaldehyde and permeabilized with 1 % 
(v/v) TritonX-100 and blocked with a 1 (w/v) % solution 
of BSA in PBS. Cells were incubated with primary 
antibody as indicated (1:1000 dilution), overnight at 4°C. 
Primary antibody was detected using Alexafluor conjugate 
secondary antibodies (Invitrogen) at 1:1000 dilution. 
Cells were counterstained with DAPI (1 µg/ml). Foci 
were detected using an In Cell Analyzer 1000 automated 
epifluorescence microscope (GE Healthcare). For all other 
immunofluorescence based experiments cells were grown 
on coverslips, fixed with 4 % (v/v) PFA and permeabilized 
with 0.1 % (v/v) Triton X-100. Coverslips were blocked 
with 3 % (w/v) BSA dissolved in PBS and incubated with 
primary antibody (1/100) prepared in blocking buffer, 
overnight at 4ºC. Coverslips were washed with PBS and 
incubated with the appropriate fluorescently conjugated 
secondary antibody (1/500) for 1 Hr at room temperature. 
Coverslips were washed (3 X PBS) and images captured 
using a Nikon 90i epifluorescent microscope or LSM 710 
(Zeiss) confocal microscope. 
For frozen tissue sections, slides were fixed in 
acetone for 10 minutes at room temperature. Slides were 
dried, washed in PBS and non-specific binding blocked 
with 3% (v/v) normal bovine serum (NBS), PBS, 0.1 % 
(v/v) Triton-X 100 for 20 minutes. Slides were incubated 
with primary and secondary antibodies as outlined above 
before image acquisition. 
Xenograft tumors and tissue microarrays (Biomax) 
were formalin fixed and paraffin embedded prior to 
sectioning and staining. Sections were re-hydrated 
sequentially from xylene – ethanol – water prior to 
antigen retrieval by boiling in 10 mM sodium citrate and 
blocked in TNB (Perkin Elmer). Endogenous peroxidise 
was blocked with 0.3 % Hydrogen Peroxide (H2O2) 
prior to all immuno-peroxidase staining protocols. Non-
specific binding of secondary antibody was blocked 
using 3 % normal serum from the animal of origin of the 
corresponding secondary antibody. Slides were incubated 
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in primary antibody (1:100) overnight at 4°C. Secondary 
antibodies were detected using Avidin Biotin Complex 
(ABC) reagent (Vector labs), followed by the chromogen 
3,3’- Diaminobenzidine (DAB) reagent (Vector labs) 
as per the manufacturer’s instructions. Sections were 
counterstained with heamatoxylin and imaged under a 
light microscope (Nikon) or the ScanScope digital slide 
scanner (Aperio). Immunohistochemical staining was 
quantified by H-score. Staining intensity was grouped 
into four categories and a numerical multiplier assigned 
(bracketed); no stain (0) low intensity (+1), moderate 
intensity (+2) and high intensity (+3). The percentage 
of cells, within each staining intensity, was multiplied 
by the multiplier to give a total H-score for comparison. 
Scoring was completed on multiple representative fields 
of view from each sample (n=3). For total scoring of 
pSer48NPM slides were scanned with the ScanScope 
digital slide scanner and total signal intensity and total 
area of positive staining from the DAB stain quantified 
by the scanscope software and grouped into scores of no 
stain, low intensity, moderate intensity and high intensity 
and scored as above. Further characterization of Pancreatic 
Ductal Adenocarcinoma was performed under guidance 
of a pathologist and specific cytoplasmic/nuclear staining 
was scored by H-Scare as outlined above.
Molecular Biology and Retrovirus Production
The following plasmids were purchased from 
Addgene; pBABE puro-myr-FLAGAKT1 (Addgene 
plasmid 15294), [104], pBABE PuroL myr-HA-
AKT2 (Addgene plasmid 9018), pBABE-puro-K-
Ras V12 (Addgene plasmid 9052) and pcDNA3 
MDM2 S166D S186D (Addgene plasmid 16236). The 
image clone (IMAGE 6411700, accession number 
BC054755) encoding mouse Npm was purchased from 
Source Bioscience. Human NPM was PCR amplified 
according to standard protocols using the primers sense- 
aatgaattcatggaagattcgatggacatggacatgagc and antisense- 
aatctcgagaagagacttcctccactgccagagatcttg and cloned into 
the C-terminal FLAG tagging vector PCMV 4 (Aligent), 
between the EcorI and XhoI restriction enzyme sites. 
Human NPM was PCR amplified using the primers NPM_
pbabe_FWD aataatggatccatggaagattcgatggacatgg and 
NPM_pbabe_REV aataatgaattcttaaagagacttcctccactgcc 
and cloned into the retroviral vector pBABE Puro 
between the BamH and EcoI restriction sites. Primers 
used for mutation of Ser48 to Ala; Hu_NPM_S48A_
sense gttatctttaagaacggtcgctttaggggctggtgcaaag & 
Hu_NPM_S48A_antisense ctttgcaccagcccctaaagc 
gaccgttcttaaagataac. Primers used for the 
mutation of Ser48 to Glu Hu_NPM_S48E_sense 
ccagttatctttaagaacggtcgagttaggggctggtgcaaaggatg 
and Hu_NPM_S48E_antisense catcctttgcaccagccccta 
actcgaccgttcttaaagataactgg. Primers used for mutation 
of siRNA (ACAAGAAUCCUUCAAGAAA) 
recognition site sense-catcaacaccaagatcaaaaggacaag
agagctttaagaaacaggaaaaaactcctaaaacac & antisense 
gtgttttaggagttttttcctgtttcttaaagctctcttgtccttttgatcttggtgttgatg. 
Mouse Npm was amplified by PCR used the primers 
Mus_Npm_Fwd aataatggatccatggaagactcgatggatatgg 
& Mus_Npm_Rev aataatgaattcttaaagagatttcctccactgcc 
and cloned into the pBABE Puro vector between the 
BamHI and EcorI restriction sites. Primers used for 
mutagenesis of Ser48 to Ala MusNpm_S48A_sense 
cagttgtcattaagaacggtcgcgttaggagcaggggcaaaagat & 
MusNpm_S48A_antisense atcttttgcccctgctcctaacgcgaccgt 
tcttaatgacaactg. Primers used for the mutagenesis 
of Ser48 to Glu MusNpm_S48E_sense ccagttgtcatt 
aagaacggtcgagttaggagcaggggcaaaagatg and MusNpm_
S48E_antisense catcttttgcccctgctcctaactcgaccgttc 
ttaatgacaactgg. Site directed mutagenesis was achieved 
using the Quikchange II kit (Agilent) according to the 
manufacturer’s instructions. 
For retroviral production and infections 6 x 106 
293T cells were seeded into a 10 cm dish 16 Hrs before 
transfection. 293T cells were transfected with 10 µg 
pBABE plasmid and 10 µg pCL-Eco packing vector using 
calcium phosphate according to standard protocols. 1 x 
105 NPM -/- P53-/- MEFs were seeded on a 10 cm dish 24 
hrs before the first infection. Virus containing supernatants 
were filtered (0.4 µm) and mixed 1:2 with fresh media and 
polybrene (8 µg/ml final concentration). NPM -/- P53-/- 
MEFs were infected a total of 3 times and 24 hrs after the 
final infection selected in complete media supplemented 
with 3 µg/ml puromycin (Sigma). Experiments were 
performed at least 3 days after selection.
Quantitative real-time PCR
PSN1 and T24 cell monolayers were treated with 
MK-2206 or DMSO control as outlined in the figure legend 
before harvesting. Samples were prepared for quantitative 
RT-PCR using Power SYBR® Green Cells-to-CT™ 
Kit (Life Technologies), according to the manufactures 
protocol. The Real-Time PCR Cycling Conditions were 
as follows: Holding Stage, 95oC for 10min (x1), Cycling 
Stage: Step 1- 95oC for 15 sec and Step 2- 60oC for 1 min 
(x 50), Melt Curve Stage (continuous): Step 1- 95oC for 
15 sec, Step 2- 60oC for 1 min, Step 3- 95oC for 30 sec 
and Step 4- 60oC for 15sec. 18S was used as an internal 
control to normalize all data. The following primers 
were used: p53 FW: ACGCTTCCCTGGATTGGCAGC 
R: GAGGGGGCTCGACGCTAGGA, p14ARF 
FW: CTACTGAGGAGCCAGCGTCTA 
R: CTGCCCATCATCATGACCT and 18S 
FW: AGTCCCTGCCCTTTGTACACA R: 
GATCCGAGGGCCTCACTAAAC. The experiments 
were carried out in triplicate for each data point.
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Clonogenic survival curves
In all clonogenic survival experiments, (200-
400) cells were plated from single cell suspensions and 
allowed to adhere to culture dishes prior to irradiation and 
/ or inhibitor exposure. Inhibitor treatment was initiated 
1 hour prior to irradiation and maintained for 24 hours. 
After the treatment interval, the medium was replaced 
with drug-free medium. Control cultures underwent 
medium replacement at the same time to control for this 
manipulation. Cells were irradiated with a Mark 1 cesium 
irradiator (J.L. Shepherd) at a dose rate of 1.7 Gy/min. 
Colonies were stained with crystal violet solution and 
counted 10 to 30 days after irradiation. The surviving 
fraction was derived using the formula: 
(# Colonies / # of cells plated) irradiated / (# Colonies / 
# of cells plated) unirradiated. 
Each point on the survival curve represents the mean 
surviving fraction from at least three dishes. Clonogenic 
survival curves are representative of independent replicate 
experiments.
3D colony growth assay
3D colony assay of the KPC mouse derived cells 
was adapted from a previously described protocol for 
3D culture of mouse pancreatic cells [105]. Cells were 
resuspended at a density of 2.5 × 103 cells/0.5 mL in 
methylcellulose-based colony culture medium. In short, 
1 mL of the culture mixture contained DMEM, 1% (wt/
vol) methylcellulose (Sigma), 5% (vol/vol) Matrigel (BD 
Bioscience), 50% (vol/vol) conditioned media from KPC 
mouse cells in culture, 5% (vol/vol) FCS, 10 mmol/L 
nicotinamide (Sigma), 10 ng/mL human recombinant 
activin-βB (R & D Systems), 0.1 nmol/L exendin-4 
(Sigma), and 1 ng/mL vascular endothelial growth 
factor–A. The cells were treated with MK-2206 (1μM, 
24hrs) prior to irradiation with a Mark 1 cesium irradiator 
(J.L. Shepherd) at a dose rate of 1.7 Gy/min for a total of 
6 Gy. Colonies were counted after 15 days using a Nikon 
Eclipse TE2000-E microscope.
xCELLigence growth assay
KPC mice derived cells were plated at a 
density of 15000 cells/ml in an E-Plate 16 (ACEA 
Biosciences,Roche) according to manufacturer’s 
instructions. The growth characteristics were 
measured using an xCELLigence RTCA DP (ACEA 
Biosciences,Roche) analyser which recorded the growth 
in terms of cell index, which is a dimensionless parameter 
derived as a relative change in measured electrical 
impedance to represent cell status. Cell Index i= (Rtn-Rt0)/
Fi where i= 1,2,3 F1=15Ω, F2=12Ω, F3=10Ω and n=0,1,2,…
N(time points).
Resazurin Assay
5 x 103 cells per well was plated in multiples of 6 
wells per condition. Fluorescence of Resofurin produced 
by conversion of Resazurin to Resofurin by viable cells 
after 48 hours following treatment with 4Gy radiation and 
/ or Doxorubicin (1µM) was read on a plate reader. 
Senescence Experiments
100 x103 T24 or DLD1 cells were seeded in a 
10 cm dish and plated in 10 % (v/v) FCS containing 
medium. Cells were swapped into 0.1 % (v/v) FCS 
containing media and following 24 hrs were treated with 
1 µM PI-103 or 5 µM MK-2206 for a further 24 hrs. In 
some experiments cells were irradiated (4 Gy) after drug 
treatment. Following drug treatment cells were swapped 
into fresh 0.1 % (v/v) FCS containing media and cultured 
at 37°C in water saturated 5% CO2/95% air. 5 days later, 
cells were fixed and stained for β-galactosidase activity. 
Cells were washed twice with PBS and fixed in 2 % 
(v/v) formaldehyde, 0.2 % (v/v) glutaraldehyde in PBS 
(15 min, at room temp). Following fixation, cells were 
washed with PBS and stained with β-Galactosidase stain 
solution (1 mg/ml X-gal (5-bromo-4-chloro-indolyl-β-D-
galactopyranoside) dissolved in dimethyl-formamide), 40 
mM citric acid/sodium phosphate buffer (pH6.0), 5 mM 
potassium ferricyanide (K3Fe(CN)6), 5 mM potassium 
ferrocyanide (K4Fe(CN)6.3H2O), 150 mM NaCl, 2 mM 
MgCl2) for 12-16 Hrs at 37ºC. Cells were viewed under a 
light microscope and those with β-galactosidase positivity 
and large cell morphology indicative of senescence were 
counted.
In-vivo xenografts
All animal procedures were performed in 
accordance with current UK legislation under an approved 
project license. Female athymic nude mice (BALB/c 
nude) (Harlan) were divided into groups receiving 
injections subcutaneously (s.c) into the flank with 1 x 
106 PSN-1 HRE luc human PCC cells with 4 x 106 LTC-
14 (stellate cells). Animals were assigned randomly into 
different groups, to receive carrier (β- cyclo-dextrin 
(1.5mg/ml)), 60 mg/kg, and 120 mg/kg of MK-2206 s/c 
on three alternate days and 320 mg/kg of MK-2206 s/c 
once, in the first experiment. Treatments were initiated 
when tumors reached 100 mm3. Animals were assigned 
randomly into different groups in the second experiment 
to receive either carrier or 60 mg/kg of MK-2206 s/c on 
two alternate days followed by irradiation, a 6 Gy single 
dose under anaesthesia on day 4. Tumor growth was 
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measured regularly by calipers. MK-2206 was made up 
in β- cyclo-dextrin (1.5mg/ml) for in vivo experiments 
at the time of randomization of animals and any made 
up drug discarded after last dose of drug was injected. 
For SQ20B xenografts PI-103 treatment, female severe 
combined immunodeficient (SCID) mice (Charles River) 
were inoculated with 106 SQ20B cells on the hind leg 
s.c. Treatments were initiated when tumors reached 100 
mm3. In all experiments, animals were treated with carrier 
(50% DMSO, 50% PBS) or PI-103 (5 mg/kg) by daily i.p. 
injections. Inhibitors were given daily for up to 2 wk. 
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